# Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion

> **NCT05203588** · PHASE4 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 116 (estimated)

## Conditions studied

- Osteoporosis
- Fusion of Spine, Lumbar Region

## Interventions

- **DRUG:** Denosumab 60 mg/ml Injectable Solution [Prolia]
- **DRUG:** calcium and vitamin D

## Key facts

- **NCT ID:** NCT05203588
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-09
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203588, "Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05203588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*